Mycophenolate after stem cell transplant for scleroderma
Treatments studied
Part of Skin clinical trials.
This trial tests whether giving mycophenolate (a drug that calms the immune system) after a stem cell transplant helps people with systemic sclerosis (scleroderma) have better long-term outcomes. It may help prevent the disease from coming back or getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have systemic sclerosis (scleroderma) and are starting a stem cell transplant at The Ottawa Hospital.
- You do not have severe kidney problems (eGFR below 25).
- Your white blood cell and platelet counts are high enough (no severe neutropenia or thrombocytopenia).
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether special cells from umbilical cord (UC-MSC) can help treat systemic sclerosis—a disease that causes skin and organ hardening. If you have early systemic sclerosis that hasn't improved enough with standard treatments, this study may offer a new option.
This research study uses special lab-grown stem cells to understand how systemic sclerosis (a disease that hardens skin and organs) develops and progresses. By studying cells from patients with different types of systemic sclerosis and healthy relatives, researchers hope to find new ways to treat or prevent the disease.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This early-phase study tests whether umbilical cord-derived “cord blood–type” cells can reduce or improve severe systemic sclerosis (a type of hardening/scarring disease of connective tissue). It may help people whose current standard treatments haven’t worked or caused side effects.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.